By Shiloh Arjun 
R&D tax credits remain one of the most valuable sources of non-dilutive funding available to UK businesses. Yet for many CFOs and finance leaders, particularly in innovation-led sectors, uncertainty around what genuinely qualifies continues to limit uptake or expose claims to unnecessary risk. This practical guide sets out how qualifying R&D activity is defined in the UK and how it applies in software, engineering and life sciences, with a clear focus on evidencing technical challenge, managing compliance risk and aligning claims with commercial reality.
Understanding Qualifying R&D Activity
At its core, HMRC defines R&D as work that seeks to achieve an advance in science or technology through the resolution of scientific or technological uncertainty. This is a technical test, not a commercial one.
To qualify, a project must demonstrate:
- An attempt to achieve an advance in science or technology
- Uncertainty that could not be readily resolved by a competent professional
- Systematic investigation or experimentation to overcome that uncertainty
For CFOs, the challenge is rarely whether innovation exists, but whether it is articulated in a way that stands up to scrutiny. Robust claims require alignment between technical teams and finance, supported by contemporaneous evidence.
Software Development: Beyond Routine Coding
Software companies are among the most frequent R&D tax credit claimants, but also among the most scrutinised.
What Typically Qualifies
Qualifying activity often arises where development goes beyond standard configuration or implementation and instead tackles fundamental technical challenges, such as:
- Developing new algorithms or architectures to improve performance, scalability or security
- Overcoming limitations in existing frameworks or platforms
- Resolving uncertainty around data processing at scale, latency or system interoperability
- Creating novel solutions where no existing software could meet the requirement
Common CFO Pain Points
- Difficulty distinguishing routine development from qualifying R&D
- Risk of overclaiming on commercial features rather than technical innovation
- Inconsistent technical documentation across agile teams
A strong claim focuses on how the problem was solved, not simply what was built.
Engineering: Innovation Hidden in Plain Sight
In engineering-led businesses, R&D is often embedded within delivery projects, making it harder to isolate and evidence.
What Typically Qualifies
Engineering R&D commonly includes:
- Designing or prototyping new products, materials or processes
- Modifying existing designs to meet new performance, safety or regulatory requirements where outcomes are uncertain
- Developing bespoke manufacturing processes or automation solutions
- Addressing failures or limitations in existing technologies
Common CFO Pain Points
- R&D activity absorbed into cost of sales or capital projects
- Uncertainty around subcontractor and externally provided worker costs
- Balancing capitalisation policies with R&D tax treatment
Engineering claims succeed when technical uncertainty is clearly separated from routine adaptation or cosmetic change.
Life Sciences: High Innovation, High Scrutiny
Life sciences companies often assume their work automatically qualifies. While the sector is inherently R&D-intensive, claims still need to meet HMRC’s strict criteria.
What Typically Qualifies
Qualifying activity may include:
- Drug discovery and formulation development
- Preclinical research addressing biological or chemical uncertainty
- Diagnostic or medical device development involving novel mechanisms
- Scaling laboratory processes to commercial manufacture where outcomes are uncertain
Common CFO Pain Points
- Managing claims alongside grant funding and state aid rules
- Distinguishing qualifying R&D from clinical trials or regulatory activity
- Ensuring cost allocation aligns with project stages
Here, precision matters. Claims must clearly articulate scientific uncertainty rather than relying on regulatory complexity or market novelty.
Cost Categories CFOs Should Scrutinise
Across all sectors, eligible costs typically include:
- Staff costs directly involved in R&D
- Externally provided workers engaged in qualifying activities
- Subcontracted R&D, subject to scheme-specific rules
- Consumables, including materials and utilities used in experimentation
- Software licences used directly for R&D purposes
CFO oversight is critical to ensure costs are accurately apportioned and defensible, particularly under increased HMRC compliance activity.
Managing Risk in a Changing Compliance Environment
HMRC’s approach to R&D tax credits has shifted decisively towards greater scrutiny. For finance leaders, this means:
- Ensuring technical narratives are prepared by competent professionals
- Maintaining clear audit trails and project documentation
- Avoiding templated or generic justifications
- Aligning R&D claims with statutory accounts and corporation tax filings
A conservative, evidence-led approach reduces enquiry risk while maximising legitimate benefit.
Strategic Value Beyond the Cash Benefit
For CFOs in software, engineering and life sciences, R&D tax credits are not simply a tax optimisation exercise. When approached correctly, they support:
- Improved visibility of innovation investment
- Stronger alignment between technical and financial strategy
- More resilient funding models alongside grants and private investment
The key is treating R&D tax as a strategic funding tool, not an afterthought.